Merkel Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Merkel cell carcinoma markets reached a value of US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.
The Merkel cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Merkel Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Merkel cell carcinoma is a rare, aggressive, and life-threatening type of cancer that develops in Merkel cells located in the skin's outer layer. The most common symptom of the ailment is the appearance of a painless, firm, shiny nodule on the skin that is usually red, pink, or purple in color. These nodules may be located anywhere on the body but are generally found on sun-exposed areas, such as the face, neck, arms, etc. Other symptoms of Merkel cell carcinoma may include itching, tenderness, pain in the affected area, bleeding from the nodule, etc. In some cases, the disease may also spread to nearby lymph nodes or other parts of the body, causing additional symptoms, such as pain, swelling, or a feeling of fullness in the affected area. Merkel cell carcinoma is often diagnosed using a physical examination, imaging tests, and a biopsy to identify any malignant cells present. In some cases, numerous additional tests, including imaging studies or blood tests, may be necessary to determine the extent of the cancer and whether it has progressed to other parts of the body.
The increasing prevalence of chronic lymphocytic leukemia, which weakens the immune system, is primarily driving the Merkel cell carcinoma market. Additionally, the rising incidences of several associated risk factors, including ultraviolet light exposure, immunosuppression, genetic mutations, etc., are also propelling the market growth. Moreover, the widespread adoption of immune checkpoint inhibitor (ICI) immunotherapy on account of its numerous associated benefits, such as lower risk of long-term tissue damage, potential for systemic anti-tumor activity, fewer side effects compared to other cancer treatments, etc., is further acting as a significant growth-inducing factor. Besides this, the increasing utilization of molecular testing for identifying specific genetic mutations and distinguishing Merkel cell carcinoma from other types of skin cancer during the diagnosis is also catalyzing the market growth. Furthermore, the escalating adoption of Mohs surgery for treating the ailment since it has a high cure rate and allows for the removal of the tumor while minimizing damage to surrounding healthy tissue is creating a positive outlook for the market. Apart from this, the emerging popularity of several innovative approaches to treatment, including surgical resection coupled with radiotherapy in patients who have failed other medications, is expected to drive the Merkel cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Merkel cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Merkel cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Merkel cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Merkel cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Merkel cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Merkel cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Merkel cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Merkel cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Merkel cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Merkel cell carcinoma across the seven major markets?
What is the size of the Merkel cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Merkel cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Merkel Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Merkel cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Merkel cell carcinoma market?
What are the key regulatory events related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by status related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the Merkel cell carcinoma market?
The Merkel cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Merkel Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Merkel cell carcinoma is a rare, aggressive, and life-threatening type of cancer that develops in Merkel cells located in the skin's outer layer. The most common symptom of the ailment is the appearance of a painless, firm, shiny nodule on the skin that is usually red, pink, or purple in color. These nodules may be located anywhere on the body but are generally found on sun-exposed areas, such as the face, neck, arms, etc. Other symptoms of Merkel cell carcinoma may include itching, tenderness, pain in the affected area, bleeding from the nodule, etc. In some cases, the disease may also spread to nearby lymph nodes or other parts of the body, causing additional symptoms, such as pain, swelling, or a feeling of fullness in the affected area. Merkel cell carcinoma is often diagnosed using a physical examination, imaging tests, and a biopsy to identify any malignant cells present. In some cases, numerous additional tests, including imaging studies or blood tests, may be necessary to determine the extent of the cancer and whether it has progressed to other parts of the body.
The increasing prevalence of chronic lymphocytic leukemia, which weakens the immune system, is primarily driving the Merkel cell carcinoma market. Additionally, the rising incidences of several associated risk factors, including ultraviolet light exposure, immunosuppression, genetic mutations, etc., are also propelling the market growth. Moreover, the widespread adoption of immune checkpoint inhibitor (ICI) immunotherapy on account of its numerous associated benefits, such as lower risk of long-term tissue damage, potential for systemic anti-tumor activity, fewer side effects compared to other cancer treatments, etc., is further acting as a significant growth-inducing factor. Besides this, the increasing utilization of molecular testing for identifying specific genetic mutations and distinguishing Merkel cell carcinoma from other types of skin cancer during the diagnosis is also catalyzing the market growth. Furthermore, the escalating adoption of Mohs surgery for treating the ailment since it has a high cure rate and allows for the removal of the tumor while minimizing damage to surrounding healthy tissue is creating a positive outlook for the market. Apart from this, the emerging popularity of several innovative approaches to treatment, including surgical resection coupled with radiotherapy in patients who have failed other medications, is expected to drive the Merkel cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Merkel cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Merkel cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Merkel cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Merkel cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Merkel cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Merkel cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Merkel cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Merkel cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Merkel cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Merkel cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Merkel cell carcinoma across the seven major markets?
What is the size of the Merkel cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Merkel cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Merkel Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Merkel cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Merkel cell carcinoma market?
What are the key regulatory events related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by status related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the Merkel cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the Merkel cell carcinoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MERKEL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 MERKEL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MERKEL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MERKEL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MERKEL CELL CARCINOMA - UNMET NEEDS
10 MERKEL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 MERKEL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Merkel Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Bavencio (Avelumab) - Merck KGaA
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda (Pembrolizumab) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MERKEL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Merkel Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 XmAb 18087 - Xencor
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 KRT-232 - Kartos Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ITI-3000 - Immunomic Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Retifanlimab - Incyte Corporation/Macrogenics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MERKEL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MERKEL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MERKEL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Merkel Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Merkel Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Merkel Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Merkel Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Merkel Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Merkel Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Merkel Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Merkel Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Merkel Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Merkel Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Merkel Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Merkel Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Merkel Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Merkel Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Merkel Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Merkel Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
16 MERKEL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MERKEL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MERKEL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MERKEL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
4.5 Competitive Intelligence
5 MERKEL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MERKEL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034?)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034?)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034?)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034?)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034?)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034?)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034?)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034?)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MERKEL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MERKEL CELL CARCINOMA - UNMET NEEDS
10 MERKEL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 MERKEL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Merkel Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Bavencio (Avelumab) - Merck KGaA
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda (Pembrolizumab) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MERKEL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Merkel Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 XmAb 18087 - Xencor
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 KRT-232 - Kartos Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ITI-3000 - Immunomic Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Retifanlimab - Incyte Corporation/Macrogenics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MERKEL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MERKEL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MERKEL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Merkel Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034?)
15.2.2 Merkel Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034?)
15.3 Market Scenario - United States
15.3.1 Merkel Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034?)
15.3.2 Merkel Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034?)
15.3.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Merkel Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034?)
15.4.2 Merkel Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034?)
15.4.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Merkel Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034?)
15.5.2 Merkel Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034?)
15.5.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Merkel Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034?)
15.6.2 Merkel Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034?)
15.6.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Merkel Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034?)
15.7.2 Merkel Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034?)
15.7.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Merkel Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034?)
15.8.2 Merkel Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034?)
15.8.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Merkel Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034?)
15.9.2 Merkel Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034?)
15.9.3 Merkel Cell Carcinoma - Access and Reimbursement Overview
16 MERKEL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MERKEL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MERKEL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
